ClinConnect ClinConnect Logo
Search / Trial NCT00346827

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

Launched by BRITANNIA PHARMACEUTICALS LTD. · Jun 29, 2006

Trial Information

Current as of July 23, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day
  • Exclusion Criteria:
  • hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females

About Britannia Pharmaceuticals Ltd.

Britannia Pharmaceuticals Ltd. is a dynamic biopharmaceutical company dedicated to the development and commercialization of innovative therapies that address unmet medical needs in various therapeutic areas. With a focus on respiratory, cardiovascular, and metabolic diseases, Britannia leverages cutting-edge research and development to enhance patient outcomes. Committed to quality and excellence, the company operates in compliance with rigorous regulatory standards and actively collaborates with healthcare professionals and research institutions. Through its robust pipeline of clinical trials, Britannia Pharmaceuticals strives to deliver safe and effective solutions that improve the quality of life for patients around the world.

Locations

Patients applied

0 patients applied

Trial Officials

Richard Weiser, MB, MRCP

Principal Investigator

Swansea Hospital, Swansea, Wales

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials